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In the melanocyte, expression of genes required for
pigment formation is mediated by the microphthal-
mia transcription factor, which is also critical for the
development and survival of normal melanocytes
during embryogenesis. Here we show that the
expression of the melanocyte-speci®c isoform of
microphthalmia transcription factor is lost in a sub-
set of human melanoma cell lines, accompanied by
the repression of tyrosinase and tyrosinase-related
proteins 1 and 2, the three transcriptional target
genes for microphthalmia. After the forced expres-
sion of microphthalmia transcription factor in mela-
noma cells where the expression of endogenous
microphthalmia gene was found to be extinguished,
no restoration of the melanogenic phenotype
occurred and the transcription of the three micro-
phthalmia transcription factor target genes remained
silent. The transcription activation domain of micro-
phthalmia transcription factor, tested as a GAL±
MITF fusion protein, remained fully functional in
these cells, however, and ectopic microphthalmia
transcription factor localized normally to the nucleus
and bound to the tyrosinase initiator E-box in gel
retardation assays. Thus, the block of differenti-
ation in microphthalmia-transcription-factor-nega-
tive melanomas extended the transcriptional repres-
sion of the microphthalmia transcription factor gene
alone, and endogenous promoters in these melanoma
cells became no longer responsive to microphthalmia
transcription factor when this was substituted exo-
genously. The data presented suggest that a speci®c
nuclear context is required for the transcriptional
activation of the melanocyte markers by the micro-
phthalmia transcription factor in malignant melano-
cytes and this speci®city is lost concomitantly with
the transcriptional repression of microphthalmia
transcription factor. Key words: melanocyte/repression/
TRP-1/tyrosinase. J Invest Dermatol 117:1505±1511, 2001
L
oss or defects of cellular differentiation are common
characteristics frequently found in cancer cells. The
crucial gene regulators important for differentiation in
many lineages are the cell-fate-determining genes of the
basic helix±loop±helix (bHLH) family of transcriptional
activators. In the melanocytes, a unique biochemical pathway
results in the formation of a visible pigment melanin, and the
enzymes involved in this pathway are considered as markers for
both normal and malignant melanocytes. The transcription of these
marker genes [tyrosinase, tyrosinase-related proteins 1 and 2
(TRP-1 and TRP-2)] is believed to be regulated by the
microphthalmia transcription factor (reviewed by Goding, 2000),
a member of the basic helix±loop±helix leucine zipper (bHLH-LZ)
family. Human (MITF) and mouse (Mitf) microphthalmia protein
sequences are almost identical and show similarities with three
other related transcriptional regulators, TFE3, TFEB, and TFEC.
Mitf can form heterodimers with these factors that bind, as do Mitf
homodimers, to the E-box consensus sequence (Hemesath et al,
1994). Tyrosinase, TRP-1, and TRP-2 are required for normal
melanogenesis in melanocytes. It has been shown that Mitf activates
promoters of all these three genes (Bentley et al, 1994; Hemesath
et al, 1994; Yasumoto et al, 1997; Bertolotto et al, 1998a; reviewed
by Goding, 2000) and also of the QNR-71 gene isolated from
pigmented cells of the retina (Turque et al, 1996). The conserved
sequence GTCATGTGCT (M-box) present in tyrosinase, TRP-1,
and TRP-2 promoters is an essential element for binding of Mitf
(Bentley et al, 1994; Hemesath et al, 1994).
In mice, mutations at the Mi locus result in defects or loss of mast
cells, osteoblasts, and retinal, cochlear, and skin melanocytes
(reviewed by Moore, 1995). Ectopically delivered MITF has
been shown to induce melanocyte-like features when introduced
into cells that normally do not express microphthalmia protein; a
dendritic morphology and induction of transcription of tyrosinase
and TRP-1 was demonstrated in MITF-expressing NIH3T3 cells
(Tachibana et al, 1996). No such effects have been observed in
10T1/2 ®broblasts, however, suggesting that only some cell types
are susceptible to the melanogenic activity of MITF (Tachibana
et al, 1996).
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Human melanoma cells either retain the capacity to undergo the
normal differentiation program (i.e., to synthesize the pigment
melanin) or are visibly amelanotic, which does not necessarily
imply that they have lost the expression of enzymes responsible for
the completion of the melanogenic pathway because additional,
post-transcriptional mechanisms regulating the melanin synthesis
exist in melanoma cells (Kameyama et al, 1993, 1995; Eberle et al,
1998). Transformation or immortalization of melanocytes in
culture by several oncogenes such as E1a, ras, neu, or basic
®broblast growth factor also causes depigmentation (Dotto et al,
1989; Melber et al, 1989; Wilson et al, 1989; Halaban et al, 1996)
and downregulation of Mitf expression (Yavuzer et al, 1995;
Halaban et al, 1996). Thus, in mouse models of melanoma,
downregulation of differentiation is an important feature accom-
panying the onset or progression of malignancy.
MITF exists in several isoforms that differ in the ®rst exon and
are transcribed from separate promoters (Amae et al, 1998).
Promoter for the melanocyte-speci®c isoform, MITF-M, is
regulated by several transcriptional factors that have been
recognized to bind to their motifs in this promoter and activate it
in reporter assays. Wnt signaling activates the LEF-1/TCF
transcription factor, which then binds to and stimulates the
MITF promoter (Takeda et al, 2000). Several recent reports have
shown that the transcriptional activators Pax3 and Sox10 are also
able to stimulate the MITF promoter (Watanabe et al, 1998;
Bondurand et al, 2000; Lee et al, 2000; Potterf et al, 2000;
Verastegui et al, 2000a). Sox10 mutant lacking the transcription
activation domain has been shown to inhibit the activation of the
MITF promoter by the wild-type Sox10 and downregulate the
levels of endogenous MITF protein, thus implicating the Sox10
protein in the regulation of MITF gene transcription in melanoma
cells (Lee et al, 2000). Moreover, the level of Mitf protein and the
activity of the microphthalmia promoter is upregulated after the
treatment of B16 mouse melanoma cells by cAMP elevating agents,
and the DNA motif to which CREB binds is required for this
stimulation (Bertolotto et al, 1996; 1998b). Due to this, transcrip-
tion of tyrosinase family members is also increased, and this
pathway thus can mediate acute transient elevation of melanin
synthesis upon hormonal stimuli.
In this study, we have found that, in human melanoma cells, the
absence of expression of the three MITF target genes (tyrosinase,
TRP-1, and TRP-2) correlates with the extinction of transcription
of the melanocyte-speci®c isoform of the MITF gene (MITF-M).
We further show that the reintroduction of MITF into melanoma
cells that have lost expression of the MITF gene does not lead to
the restoration of the differentiated phenotype. The inability of
MITF to induce melanogenesis in the MITF-negative cells is not
due to the functional inhibition of the transcription activation
domain or the impaired nuclear localization. These results show
that when MITF is transcriptionally repressed in a subset of human
melanomas, promoters of MITF-regulated marker genes, in the
chromatin context, become nonresponsive to otherwise functional
exogenous MITF.
MATERIALS AND METHODS
Cell lines Human melanoma cell lines used in this study were
purchased from the American Type Culture Collection (Manassas, VA)
except for cell lines IgR3, Beu, Dor, Dau, LND1, Hbl, and Scl, which
have been described previously (DelMarmol et al, 1993). All melanoma
cell lines were maintained in Eagle's minimal essential medium,
supplemented with 10% fetal bovine serum (FBS) (Gibco), 50 units per
ml penicillin, 50 cËg per ml streptomycin, 2 mM L-glutamine, and 1 mM
sodium pyruvate. Other cell lines used here were cultivated in
Dulbecco's modi®ed Eagle's medium containing 10% FBS, antibiotics,
and L-glutamine.
Plasmids and constructs Human MITF cDNA was recovered from
normal human melanocytes by using reverse transcription polymerase
chain reaction (RT-PCR) with primers 5¢-CGC GAA GCT TGT TAT
GCT GGA AAT GCT A and 5¢-ACG CGA ATT CGC ACA ACA
AGT GTG CTC CGT CTC (stop codon abolished) containing HindIII
and EcoRI sites, respectively, for subsequent cloning. Double-stranded
oligonucleotide with the sequence encoding the hemaglutinin (HA)
epitope followed by a stop codon (5¢-AATTGTTACCCCTACGACG-
TGCCCGACTACGCCTCCCTCGCTTAGAG) was then cloned into
the EcoRI site resulting in the C-terminal-tagged MITF (MITF-HA)
and the insert was sequenced on both strands. The sequence
corresponded exactly to the reported human MITF cDNA (Tachibana et
al, 1994). For use in transient transfections, the MITF-HA sequence was
cloned into the pcDNA3 expression vector (Invitrogen, Carlsbad, CA)
to obtain pCMV-MITF-HA. The HA epitope was added in order to
discriminate ectopic MITF from possible low levels of the two
ubiquitous isoforms of MITF, MITF-A and MITF-H (Amae et al, 1998;
Vachtenheim and Novotna, 1999), which could react with the anti-
MITF antibody in indirect immuno¯uorescence. Also, the internal
BamHI±BamHI fragment that comprises the entire bHLH-LZ region of
MITF was cut off and the shortened plasmid was religated (in frame,
after ®lling) to obtain pCMV-MITF-(DbHLH-LZ)-HA, which served as
a negative control in transfections. The human tyrosinase promoter
sequence that contains bases ±300 to +80 relative to the transcription
start (Bentley et al, 1994) was cloned into the pGL3 basic reporter vector
(Promega, Madison, WI) to yield pTyr-prom-Luc and used in transient
transfections. The plasmid pCMV-GAL4-BD-MITF(105±199) contains
sequences encoding amino acids 105±199 of MITF fused in frame to the
GAL4 DNA-binding domain. The reporter plasmid pG5-E1b-TATA-
Luc was cloned by placing the ®ve GAL-binding sites with the minimal
E1b promoter region from pG5CAT (Clontech, Palo Alto, CA)
upstream of the luciferase gene in the pGL3 enhancer (Promega).
RT-PCR and southern blot The expression of the endogenous
genes was determined by the RT-PCR method. Total RNA from
melanoma cell lines or transfected cells was isolated by the guanidium
thiocyanate procedure and 1 cËg of RNA was reverse transcribed with
Superscript II (Life Technologies, Gaithersburg, MD) according to the
instructions of the supplier. The primer pairs employed in PCR and the
length of the corresponding PCR product were as follows: melanocyte-
speci®c isoform of MITF (MITF-M), 5¢-AGG GAG GGA TAG TCT
ACC GTC TCT C and 5¢-GCA GGG AGG ATT CGC TAA CAA
GTG T (1328 bp product); tyrosinase, 5¢-TTG GCA GAT TGT CTG
TAG CC and 5¢-AGG CAT TGT GCA TGC TGC TT (283 bp
product) (Eberle et al, 1995); TRP-1, 5¢-TCT TTC TCC CTT CCT
TAC TGG and 5¢-CAT TTC TGT GTT GGT GAC TGG (630 bp
product); TRP-2, 5¢-CCC GAA TTC GAG CTC TCC CAA TTA
TAA AGC CAT and 5¢-CCC GAA TTC AGG TAA GGC ATG AGC
ACC CTA G (1618 bp product). Primers for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were from Clontech (Palo Alto,
CA). No ampli®cation was seen when the reverse transcription was
omitted. Identity of the PCR products was con®rmed by sequencing.
Southern blotting of DNA samples was performed on Hybond N+
membranes (Amersham Pharmacia Biotech, U.K.) according to the
manufacturer's instructions and probed with the MITF 32P-labeled
cDNA probe encompassing the whole protein coding region.
Retroviral transfer of MITF To prepare amphotrophic retroviral
stocks, MITF-HA insert was cloned in the retroviral vector pBABEpuro
(Morgenstern and Land, 1990) and transfected into y-2 cells, and the
transient virus was used to infect amphotropic PA317 packaging cell line.
0.45-mm-®ltered medium from transiently infected PA317 cells was used
to infect human melanoma cells IgR3 and RPMI7951 in the presence of
4 mg per ml Polybrene (Sigma) for 2 h as described previously (Yavuzer
et al, 1995). After 2 d, infected cells were selected in 0.3 mg per ml
puromycin and resistant clones or pools were expanded 1 wk later and
analyzed.
Cell transfections and luciferase assays For transient transfections,
cells were seeded in six-well plates a day prior to transfection. U2OS,
C33A, and H1299 cells were transfected by the calcium phosphate
method (Chen and Okayama, 1991) and 0.25 mg of the plasmid pCMV-
b was included in the plasmid mix to normalize the variability in
transfection ef®ciency. The reporter plasmid pG5-E1b-TATA-Luc
(0.5 mg) and various amounts of pCMV-GAL4-BD-MITF(105±199)
were cotransfected and the cells were harvested 48 h later and assayed for
luciferase and b-galactosidase activities. IgR3, RPMI7951, and SK-MEL-
5 cells were transiently transfected with lipofectamine (Life
Technologies) in 400 ml of Opti-Mem medium in 12-well plates
overnight, and harvested 48 h later. In lipofections, 20 ng of the
expression plasmid encoding Renilla luciferase was used to normalize the
luciferase values by determining the dual luciferase activity (Promega).
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Western blotting, immuno¯uorescence, and gel mobility shift
assays The expression of MITF-HA protein was determined by
Western blotting of nuclear extracts and probing with the D5
monoclonal antibody to MITF (Hemesath et al, 1998) (obtained from
LabVision, Fremont, CA). Proteins were visualized by enhanced
chemiluminescence (Amersham Pharmacia Biotech). For immuno-
¯uorescence, the cells were grown on coverslips, ®xed with 3%
paraformaldehyde in phosphate-buffered saline (PBS), permeabilized for
10 min in 0.2% Triton X-100 in PBS, blocked in 5% sheep serum, 2%
bovine serum albumin, and 0.05% Nonidet P-40 in PBS, and stained
with anti-HA antibody 12CA5 (Roche, Mannheim, Germany) diluted to
a ®nal concentration of 1 mg per ml in the blocking solution. The
second antibody was a 1:50 diluted ¯uorescein isothiocyanate (FITC)
labeled antimouse IgG (Roche). Gel mobility shift assays were carried
out as described previously (Bertolotto et al, 1998a) except that poly(dI-
dC) was omitted from the binding mix and the polyacrylamide gel
contained 10% glycerol. Primers derived from the human tyrosinase
promoter sequence (GTCTCAGCCAAGACATGTGATAATCA and
ACAGTGATTATC
ACATGTCTTGGCTG) were annealed and this double-stranded probe
containing the tyrosinase initiator E-box was labeled with a-32P-dCTP
and Klenow ®lling and used in gel mobility shifts.
RESULTS
Three MITF target genes, tyrosinase, TRP-1, and TRP-2, are
expressed only in MITF-M-positive melanoma cells We
have previously reported that the MITF-M isoform constitutes the
vast majority of the MITF-related messenger RNA in human
melanoma cell lines and have observed the loss of this melanocyte-
speci®c MITF-M isoform in a few cell lines (Vachtenheim and
Novotna, 1999). If MITF is necessary for the expression of the target
genes in melanocytes, we asked whether the expression of mRNA
for MITF-M and MITF-regulated melanogenic markers correlates
in human melanoma cell lines. The analysis by RT-PCR revealed
that indeed the loss of MITF transcript in the three cell lines
RPMI7951, IgR3, and Dau correlated with the absence of
tyrosinase, TRP-1, and TRP-2 mRNAs (Fig 1). In RPMI7951
melanoma cells, however, a very low level of tyrosinase message was
still detectable even in the absence of MITF, and A375 cells
expressed only a low level of MITF but no marker gene (Fig 1).
Although the pattern of expression of tyrosinase and TRP-2 mRNA
almost faithfully copied that of MITF, the TRP-1 transcript was
selectively repressed in several melanomas (SK-MEL-2, Dor, LND1,
Beu, SK-MEL-1, and SK-MEL-31). Northern blot analyses
con®rmed the RT-PCR results (not shown). To verify that the
loss of MITF transcription was due to transcriptional repression and
not a consequence of gene rearrangement, southern blot was
performed on MITF-message-negative and selected MITF-
message-positive melanomas and the pattern of fragments was
found to be essentially the same (Fig 2). Thus, no gross gene
abnormality or a chromosomal translocation involving the MITF
gene underlies the loss of MITF mRNA in the three melanoma cell
lines.
Ectopic MITF induces transcription of endogenous
tyrosinase gene in U2OS cells Transfected MITF has been
demonstrated to activate promoter±reporter constructs of the three
melanogenic genes tyrosinase, TRP-1, and TRP-2 (Bentley et al,
1994; Yasumoto et al, 1997; Bertolotto et al, 1998a) and to induce
transcription of the endogenous tyrosinase and TRP-1 in NIH3T3
cells (Tachibana et al, 1996). To further explore the role of MITF
in melanocytic differentiation, we wished to determine the effect of
ectopically expressed MITF in melanoma cells in which the
endogenous protein was found to be extinguished. It was essential
to con®rm ®rst that the HA-tagged MITF construct was functional.
When transfected into COS7 cells, the pCMV-MITF-HA vector
activated the tyrosinase promoter±reporter about 5-fold whereas
the deleted form of MITF missing the DNA-binding and
dimerization domains [pCMV-MITF-(DbHLH-LZ)-HA] was
inactive (Fig 3A). Similar levels of activation were found in
several other cell types unrelated to melanocytes (not shown). The
in vitro translated product bound to the M-box and initiator E-box
derived from the tyrosinase promoter, as determined by gel shifts
(not shown). Importantly, as shown in Fig 3(B) (lane 2), MITF
provoked the expression of the endogenous tyrosinase gene in
U2OS cells (human osteosarcoma), whereas the transfection of an
empty vector or the pCMV-MITF-(DbHLH-LZ)-HA plasmid did
not elicit any response (Fig 3B, lanes 1 and 3). This induction of
the tyrosinase gene in U2OS cells, which are normally negative for
melanogenic markers, was consistently observed in all transfection
experiments (repeated many times); however, the two other
endogenous genes, TRP-1 and TRP-2, remained silent in these
cells (not shown). Nevertheless, these results demonstrate that the
MITF-HA expression construct was fully functional. Consistent
with the functional assays, ectopic MITF-HA localized
predominantly to the nucleus in transfected U2OS cells (Fig 3C).
Exogenous MITF does not reactivate target genes in MITF-
message-negative melanoma cells We then asked whether
the forced expression of MITF can restore the melanocytic
phenotype in melanoma cell lines where MITF transcription was
repressed. To this end, we ®rst tested whether the pCMV-MITF-
HA construct stimulates the transiently transfected tyrosinase
Figure 1. Expression of MITF and the three target genes
analyzed by RT-PCR in human melanoma cell lines. The analysis
was carried out with two independent isolations of RNA and the results
of one experiment are shown. No bands were seen when the reverse
transcriptase step was omitted. PCR proceeded for 30±35 cycles, except
for GAPDH, which was stopped after 25 cycles. For the lengths of the
PCR products see Materials and Methods. HeLa S3 cells did not express
any melanocyte marker and normal human melanocytes were positive for
all mRNAs (not shown). Figure 2. Analysis of the genomic microphthalmia locus in
MITF-message-negative melanoma cell lines. 10 mg of genomic
DNA was cleaved with either EcoRI (left) or BamHI (right) and
subjected to electrophoresis and southern blotting. MITF cDNA was
used as a probe.
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promoter±reporter in these cell lines. As in COS7 cells (Fig 3A)
and in several other cell lines (not shown), pCMV-MITF-HA
activated the transiently delivered tyrosinase promoter in two
human melanoma cell lines IgR3 and RPMI7951 (Fig 3D), which
were devoid of any MITF-M mRNA (Fig 1). Unlike U2OS cells,
however, these two cell lines did not support the induction of
endogenous tyrosinase by transiently transfected MITF (data not
shown). We therefore introduced MITF-HA via retroviral
infection into these two melanoma cell lines and analyzed the
selected clones (the third MITF-negative cell line Dau was not used
because of its slow proliferation rate and very low transfection
ef®ciency). Figure 4 (lanes 1, 2) shows an example of this
experiment: the two puromycin-resistant clones of the MITF-
HA-transduced IgR3 cells that express MITF mRNA and protein
levels comparable to those seen in differentiated melanoma lines
expressing endogenous MITF, SK-MEL-5 and SK-MEL-28
(Fig 4, lanes 4 and 5, respectively). Importantly, the ectopic
MITF-HA was not suf®cient to induce the transcription of the
endogenous tyrosinase gene, as detected by northern blot or RT-
PCR (Fig 4, lanes 1, 2). As a positive control, a strong signal of the
tyrosinase message was observable in the pigmented melanoma cells
containing comparable levels of MITF protein (Fig 4, lanes 4, 5).
U2OS cells transiently transfected with the MITF-HA vector
showed the tyrosinase signal on RT-PCR gel, whereas the MITF
protein was still below the detection limit of the D5 antibody
(Fig 4, lane 7). Further, several clones or pools of transduced
RPMI7951 cell line and several additional clones of infected IgR3
cells where MITF protein was detectable by Western blot likewise
did not reveal any onset of transcription of the target genes (results
not shown). These ®ndings suggest that, whereas the transiently
transfected promoter can be activated (Fig 3D), an unknown
mechanism prevents the activation of the endogenous MITF-
regulated genes by forced expression of MITF. We also did not
observe any signi®cant effects of MITF on cell morphology or
growth rate in any of the puromycin-resistant clones derived from
IgR3 or RPMI7951 (not shown).
The MITF transcription activation domain is functional in
all cells tested independently of their melanogenic potential,
and ectopic MITF binds to DNA in vitro The N-terminal part
of Mitf is able to activate transcription and the activation domain
can be further narrowed to a core motif of amino acids 114±132
(Sato et al, 1997). Therefore, to elucidate the function of the MITF
transactivation domain, we evaluated the ability of the sequences
involved in activation (amino acids 105±199 fused to the GAL4-
DB domain) to stimulate transcription from the GAL reporter in
cell lines with different melanogenic potential. A strong, dose-
dependent activation of the luciferase activity was found in all cell
types tested (Fig 5A). When the highest amount of the GAL±
MITF construct was transfected, the stimulation ranged from about
22-fold in RPMI7951 cells to 130-fold in IgR3 cells (Fig 5A, left
and right panels). These results indicate that the strength of the
activation domain does not depend on whether the cells have a
Figure 4. Retrovirally transduced MITF does not restore the
transcription of melanogenic markers in clones of IgR3 cells.
Puromycin-resistant clones of IgR3 cells (clones 8 and 9) with
retrovirally transduced MITF-HA (lanes 1, 2), control IgR3 cells (lane 3),
two differentiated melanoma cell lines SK-MEL-5 and SK-MEL-28
(lanes 4, 5) as positive controls, HeLa cell line (lane 6) as a negative
control, and transiently transfected U2OS cells (lanes 7, 8) are shown.
(A) Northern blot was probed with the MITF cDNA probe; (B)Western
blot was performed with the anti-MITF D5 monoclonal antibody; (C)
the same northern blot as in (A) reprobed with the human tyrosinase
cDNA; (D) RT-PCR analysis of the tyrosinase mRNA; (E) ethidium
bromide staining of 28S RNA of a gel used for northern blot; (F)
control RT-PCR analysis (GAPDH). IgR3 cells transduced with an
empty retroviral vector gave the same results as native IgR3 (not shown).
The HA-tagged MITF protein is retarded in migration (B, lanes 1 and 2,
left arrow) compared to the endogenous one due to the epitope tagging.
Endogenous protein is marked by an arrow in lane 4.
Figure 3. Testing the expression construct for MITF. (A)COS7
cells were transiently transfected with the vector alone (lane 1), pCMV-
MITF-HA (lane 2), or pCMV-MITF(DbHLH-LZ)-HA (lane 3) and the
reporter plasmid pTyr-prom-Luc. pCMV-b was cotransfected to
normalize transfection ef®ciency. (B)U2OS cells were transfected with
the expression plasmids as in (A) and the expression of endogenous
tyrosinase was detected by RT-PCR (lane 4 represents the positive
control from the melanoma cell line DOR). (C) Cellular localization of
the MITF protein expressed from the pCMV-MITF-HA plasmid
revealed by staining with the anti-HA antibody 12CA5 in U2OS cells.
(D) MITF stimulated the tyrosinase promoter±reporter in IgR3 and
RPMI7951 cell lines. The transfected plasmids were the same as in (A).
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melanogenic potential or not. Several other cell lines that did not
support the activation of endogenous tyrosinase by MITF in
transient transfections (NIH3T3, A549, ras-transformed mouse
melanocytes, and COS7) likewise revealed a similar pattern of
activation by the GAL±MITF(105±199) fusion construct (data not
shown). The data together indicate that the domain of MITF
responsible for transcriptional activation is not inhibited in cells
where the full-length functional MITF could not activate the
endogenous tyrosinase gene. Furthermore, subcellular localization
of MITF-HA protein was nuclear in IgR3 and RPMI7951 cells
(Fig 5B) as well as in other cell types tested (not shown).
To test whether ectopic MITF present in nuclear extracts of
IgR3-derived clones (Fig 4) could bind to DNA in vitro, we
carried out gel mobility shift assays. As the tyrosinase initiator
E-box sequence is essential for the activation of the tyrosinase
promoter by MITF (Bentley et al, 1994), we used it as a probe in
gel retardation assays. Pigmented melanoma cell lines SK-MEL-5
and SK-MEL-28 used as controls showed strong supershifted bands
upon addition of anti-MITF antibody (Fig 5C). The IgR3-derived
MITF-expressing clones 8 and 9 likewise revealed this supershift,
and although the supershifted band was attenuated compared to
pigmented melanomas, these data clearly demonstrated that exo-
genous MITF could bind its consensus DNA sequence. No binding
was seen in IgR3 cells (Fig 5C). Thus, as the endogenous targets
were not activated, these experiments suggest that the binding of
exogenous MITF to DNA may be nonproductive in IgR3-derived
clones.
DISCUSSION
We have determined the expression of several genes related to
differentiation in human melanomas, including the bHLH-LZ cell-
fate-determining gene MITF. Three of 17 melanoma cell lines
showed total repression of MITF-M gene transcription, accom-
panied by the repression of all three MITF transcriptional targets.
Furthermore, TRP-1 gene was selectively repressed in several
MITF-positive cell lines, suggesting the existence of a speci®c
repressor for the TRP-1 gene. Similar repression of TRP-1 has
been reported earlier on several other melanoma cell lines;
however, the MITF expression has not been analyzed (Eberle
et al, 1995). A candidate gene for this repression function could be
the Tbx2 protein, a T-box family member implicated in limb
development, because Tbx2 was shown recently to repress the
mouse TRP-1 promoter by binding to the speci®c Tbx2 binding
site (Carreira et al, 1998). Our results thus support the idea that
TRP-1 gene expression, besides its requirement for MITF, is
regulated by additional mechanisms. It is interesting that MITF has
also been proposed to transactivate the promoter of the mouse
Tbx2 gene and the Tbx2 protein has been found expressed in
pigmented mouse melanocytes and melanomas (Carreira et al,
2000). We have not determined here the expression pattern of the
human Tbx2 gene in a panel of human melanomas. Clearly, further
studies are needed to establish if Tbx2 is an in vivo target of MITF
and the possible physiologic role of Tbx2 in melanocytes.
In studies demonstrating the extinction of pigmentation in
microcell hybrids, it was reported that human and mouse ®broblasts
contain an extinguisher locus that suppresses the transcription of
melanocyte marker genes (Powers et al, 1994; Powers and
Davidson, 1996). It has been suggested that this extinction, in
hybrids of mouse ®broblasts and hamster melanoma cells, could be
due to the repression of microphthalmia (Powers and Davidson,
1996). Therefore, it is possible that an extinguisher locus has been
activated in a few melanomas in the process of dedifferentiation.
In this paper we further report that melanoma cells de®cient in
microphthalmia protein expression are unable to reexpress
endogenous MITF targets after the forced expression of MITF.
These dedifferentiated melanoma cells thus resemble nonmelano-
cyte lineages rather than the original melanocytes. The transcrip-
tional activity and degradation of the microphthalmia protein is
post-translationally regulated by phosphorylation on serines S73
and S409, and the S73 MAPK-phosphorylated species binds the
p300 coactivator and is more potent in transcription from the
tyrosinase promoter±reporter (Hemesath et al, 1998; Wu et al,
2000). This phosphorylated MITF protein appears as a retarded
band on sodium dodecyl sulfate polyacrylamide gel electrophoresis
(Hemesath et al, 1998) and we have also observed this slowly
migrating band as a major MITF form on Western blot (Fig 4B). It
is therefore unlikely that the inability of ectopic MITF to induce
endogenous targets in IgR3 and RPMI7951 cells would be a result
of insuf®cient phosphorylation by the MAPK pathway (Erk-2
kinase) in these cells.
Another reason underlying the inability of MITF to reactivate
the differentiation program in MITF-negative melanomas could be
that an essential heterodimeric partner of MITF required for the
transcriptional activation was repressed concomitantly with MITF.
MITF homodimers as well as heterodimers with TFEB, TFEC, and
Figure 5. Stimulation of GAL-responsive reporter by the MITF
activation domain in various cells, subcellular localization of
MITF in IgR3 and RPMI7951 cells, and DNA-binding activity of
MITF. (A) The indicated amounts of the GAL±MITF fusion plasmid
were transfected together with the reporter gene and the stimulation of
luciferase activity was measured after 48 h. Each experiment was
performed three to ®ve times (in duplicate samples) and one
representative set of results is shown with standard deviation. (B) Cells
grown on coverslips were transfected with the pCMV-MITF-HA
plasmid and analyzed 48 h later. Immuno¯uorescence was performed by
staining cells with the anti-HA antibody 12CA5. Shown are IgR3
melanoma cells (left) and RPMI7951 melanoma cells (right). Selected
clones of cells with retrovirally transduced MITF-HA gave the same
pattern of localization (not shown). (C) Gel shift assays with nuclear
extracts prepared from the indicated cell lines. E-box derived from the
tyrosinase promoter initiator sequence was used as a probe. Arrow
indicates the supershift produced by the anti-MITF antibody (D5). Non-
immune IgG did not cause any supershift (not shown).
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TFE3 bind ef®ciently to the E-box (Hemesath et al, 1994).
Evolutionarily closest to MITF is TFE3, which seems to be widely
expressed (Rehli et al, 1999), but its expression in melanomas has
not been studied. Only recently, although TFE3 was demonstrated
to stimulate tyrosinase and TRP-1 promoters in reporter assays,
endogenous TFE3 homodimers did not bind to the M-box and
MITF±TFE3 heterodimers were not found in B16 mouse mela-
noma cells (Verastegui et al, 2000b). It is thus uncertain what
complexes operate in vivo or whether additional factors are required
to activate MITF recruited to the tyrosinase promoter in a speci®c
cellular context. It is believed, however, that MITF can activate
transcription in the absence of any other member of the MiT
subfamily. We have also observed here that exogenous MITF in
IgR3-derived clones could bind the tyrosinase initiator E-box in
gel retardation assays. This would indicate that nuclear extracts do
not contain inhibitors preventing the MITF±DNA interaction
in vitro. We cannot, however, exclude the possibility that in vivo this
binding does not occur, for instance due to the nucleosome
repositioning or acquiring a state of remodeled nucleosomes around
the tyrosinase promoter that does not favor the in vivo binding.
Several recent reports have suggested that microphthalmia
protein can be a speci®c and useful marker for malignant
melanoma, being present in almost all specimens of pigmented
melanomas (King et al, 1999; 2001). In contrast, only a subset of
desmoplastic melanomas was stained by the anti-MITF antibody
(King et al, 2001; Busam et al, 2001; Koch et al, 2001; Miettinen et
al, 2001). Although we could not verify whether the IgR3 and
RPMI7951 melanoma cells used in this work were originally
diagnosed as desmoplastic melanomas, it is notable that RPMI7951
cells originally formed pigmented melanomas in nude mice (as
mentioned in the ATCC cell data sheet), and thus MITF
expression might have been lost during the propagation. Further,
given that microphthalmia plays a fundamental role in the survival
of embryonal melanocytes and is expressed in virtually all
melanoma specimens (King et al, 1999), it can be speculated that
MITF also plays a role in the proliferation of malignant
melanocytes. If so, when the expression of MITF is lost in
malignant melanocytes, as in desmoplastic melanomas, they must
develop a program independent of MITF to sustain proliferation. If
MITF is then no longer required for proliferation or survival of
these dedifferentiated tumor cells, the target promoters are not
activated and ultimately may become nonresponsive to MITF, if
this is delivered later ectopically. This nonresponsiveness of the
natural MITF targets to forced expression of MITF, as described in
this paper, would be compatible with this hypothesis. Our results
thus warrant further search for yet unknown downstream genes
transcriptionally regulated by MITF that might prove to be
important for the proliferation of malignant melanocytes.
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